FindTrial
Sign In

Temozolomide SUN 100 mg hard capsules

DRUG7 trials

Sponsors

Debiopharm International S.A., Bristol-Myers Squibb Services Unlimited Company, Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., Institut De Recherches Internationales Servier IRIS, Helse Bergen HF

Conditions

Diffuse Midline GliomaGlioblastomaGrade IV recurrent glioma which includes both glioblastomaH3K27-alteredIDH1-mutant GliomaIDH2-mutant GliomaPan tumorclassified as IDH wt and grade IV IDH mutated astrocytoma.

Phase 1

A phase 1/2 open-label study of Debio 0123 in combination with temozolomide in adult participants with recurrent or progressive glioblastoma and of Debio 0123 in combination with temozolomide and radiotherapy in adult participants with newly diagnosed glioblastoma
RecruitingCTIS2022-502156-31-00
Debiopharm International S.A.Glioblastoma
Start: 2023-05-26Target: 55Updated: 2025-11-03
BORTEZOMIB SENSITIZATION OF RECURRENT GRADE-4 GLIOMA WITH UNMETHYLATED MGMT PROMOTER TO TEMOZOLOMIDE. PHASE IB/II. (BORTEM 17)
RecruitingCTIS2024-515142-16-00
Helse Bergen HFclassified as IDH wt and grade IV IDH mutated astrocytoma., Grade IV recurrent glioma which includes both glioblastoma
Start: 2024-10-03Target: 63Updated: 2024-10-02
A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma
Active, not recruitingCTIS2024-513738-39-00
Institut De Recherches Internationales Servier IRISIDH1-mutant Glioma, IDH2-mutant Glioma
Start: 2025-03-18Target: 17Updated: 2025-12-18
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus standard temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma.
Not yet recruitingCTIS2024-516357-46-00
Philogen S.p.A.Glioblastoma
Target: 70Updated: 2025-03-14
FIDES: Focused Ultrasound-mediated Blood-Brain Barrier Opening In Pontine Diffuse Midline Glioma (DMG) to Enhance Systemic Therapy with Temozolomide – an exploratory pilot and feasibility trial
Not yet recruitingCTIS2025-520814-78-00
Universitair Medisch Centrum UtrechtDiffuse Midline Glioma, H3K27-altered
Target: 20Updated: 2026-03-23

Phase 2

Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
RecruitingCTIS2023-506914-32-00
Bristol-Myers Squibb Services Unlimited CompanyPan tumor
Start: 2020-05-05Target: 307Updated: 2026-01-19
Vaccination with Autologous Dendritic cells loaded with Autologous Tumour homogenate in Glioblastoma: a phase II Study (Combi G-Vax)
RecruitingCTIS2024-512493-98-00
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.Glioblastoma
Start: 2021-03-25Target: 28Updated: 2024-07-15